Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCalnex Solutio. Regulatory News (CLX)

Share Price Information for Calnex Solutio. (CLX)

Share Price is delayed by 15 minutes
Get Live Data
68.50    0.00 (0.00%)
Bid:
67.00
Ask:
70.00
Spread: 3.00 (4.478%)
Market Cap: £60.33m
CLX Live PriceLast checked at - London Stock Exchange

Intraday Calnex Solutio. Share Chart

Exercise of Options

14 Feb 2024 13:08

RNS Number : 1572D
Calnex Solutions PLC
14 February 2024
 

Calnex Solutions plc

 

("Calnex" or the "Company")

 

Exercise of Options

 

Calnex Solutions plc (AIM: CLX), a leading provider of test and measurement solutions for the global telecommunications and cloud computing markets, announces that the Company has issued a total of 16,667 new ordinary shares of 0.125 pence each ("New Shares"), pursuant to the exercise of options issued under the Company's EMI Share Option Plan.

 

Application will be made for the admission of the New Shares to trading on AIM ("Admission"). The New Shares will rank pari passu with the existing Ordinary Shares and it is expected that Admission will become effective at 8.00 a.m. on 16 February 2024.

 

Following Admission, the Company's issued share capital will consist of 87,540,602 Ordinary Shares with voting rights. Calnex does not hold any Ordinary Shares in treasury. This figure of 87,540,602 may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they require to notify their interest in, or a change to their interest in, the share capital of the Company under the UK Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

 

 

 

For more information, please contact:

Calnex Solutions plc

Via Alma

Tommy Cook, Chief Executive Officer

Ashleigh Greenan, Chief Financial Officer

Cavendish Capital Markets Limited - NOMAD

+44 (0)131 220 6939

Derrick Lee, Peter Lynch

 

Alma

+44(0) 20 3405 0213

Caroline Forde, Hannah Campbell, Joe Pederzolli

 

Overview of Calnex

Calnex Solutions designs, produces and markets test and measurement instrumentation and solutions for the telecommunications and cloud computing industries. Calnex's portfolio enables R&D, pre-deployment and in-service testing for network technologies and networked applications, enabling its customers to validate the performance of the critical infrastructure associated with telecommunications and cloud computing networks and the applications that run on it.

 

To date, Calnex has secured and delivered orders in 68 countries across the world. Customers include BT, China Mobile, NTT, Ericsson, Nokia, Intel, Qualcomm, IBM and Meta.

 

Founded in 2006, Calnex is headquartered in Linlithgow, Scotland, with additional locations in Belfast, Northern Ireland, Stevenage, England and California in the US, supported by sales teams in China and India. Calnex has a global network of partners, providing a worldwide distribution capability. 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IOETIMJTMTMBBFI
Date   Source Headline
1st Jun 20267:30 amRNSDirector Dealing
29th May 20263:00 pmRNSExercise of Options and Total Voting Rights
26th May 20267:00 amRNSFinal Results
14th May 20267:00 amRNSNotice of Presentations
13th Apr 20267:00 amRNSFY26 Trading Update and Notice of Results
30th Mar 20267:00 amRNSHolding(s) in Company
26th Nov 20257:30 amRNSDirector Dealing
18th Nov 20257:00 amRNSInterim Results
6th Nov 202511:30 amRNS-RCalnex and Viavi Partnership
30th Oct 20257:00 amRNSNotice of Results and Presentations
8th Oct 20252:08 pmRNSExercise of Options and Total Voting Rights
16th Sep 20259:09 amRNSExercise of Options and Total Voting Rights
14th Aug 20254:12 pmRNSResult of AGM
14th Aug 20257:00 amRNSAGM Statement
15th Jul 20257:00 amRNSNotice of AGM and posting of Annual Report
16th Jun 20259:52 amRNSLong-Term Incentive Plan Awards
10th Jun 202511:59 amRNSDirector Dealing
20th May 20257:00 amRNSFinal Results
15th May 20257:00 amRNSNotice of Investor Presentation
8th Apr 20257:00 amRNSFY25 Trading Update and Notice of Results
14th Mar 20257:00 amRNSDirector Dealing
29th Jan 202510:48 amRNSExercise of Options
19th Nov 20247:00 amRNSInterim Results
4th Nov 20247:00 amRNSNotice of Results and Investor Presentation
8th Oct 20247:00 amRNSDirector/PDMR Dealing
2nd Oct 20244:57 pmRNSResult of General Meeting
6th Sep 20247:00 amRNSNotice of General Meeting
22nd Aug 20245:18 pmRNSResult of AGM
22nd Aug 20247:00 amRNSAGM Statement
18th Jul 20249:08 amRNSNotice of AGM
17th Jul 20242:00 pmRNSLong-Term Incentive Plan Awards
21st May 20247:00 amRNSFY24 Final Results
10th Apr 20247:00 amRNSNotice of Investor Presentation
3rd Apr 20247:00 amRNSFY24 Trading Update and Notice of Results
21st Feb 20249:28 amRNSExercise of Options
14th Feb 20241:08 pmRNSExercise of Options
12th Dec 20233:47 pmRNSPDMR Dealings
21st Nov 20237:00 amRNSInterim Results
1st Nov 202312:24 pmRNSChange of Nominated Adviser
26th Oct 20237:00 amRNSNotice of Investor Presentation
10th Oct 20233:17 pmRNSTrading Update and Notice of Results
25th Aug 20234:36 pmRNSPDMR Dealings
16th Aug 20231:22 pmRNSResult of AGM
16th Aug 20237:00 amRNSAGM Statement
11th Aug 20232:00 pmRNSLong-Term Incentive Plan Awards
17th Jul 20237:00 amRNSNotice of AGM
12th Jul 202312:05 pmRNSDirector/PDMR Dealings
12th Jun 20234:34 pmRNSPDMR Dealings
23rd May 20237:00 amRNSFY23 Final Results
11th May 20239:00 amRNSPDMR Dealings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.